Effect of Tab Glucitox in the management of Diabetis Mellitus

Evaluation of Efficacy of Tab.Glucitox in Patients of type 2 Diabetes Mellitus - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2024/05/067188

Enrollment

Registered

2024-05-10

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Confirmed case of DM (NIIDDM or Type II DM) Uncomplicated Fasting BSL more than 125mg/dl less than or equal to 200mg/dl PP BSL more than 200mg/dl equal to or less than 400mg/dl HbA1c more than 7 % and 10 % Patients with informed written consent

Exclusion criteria

Exclusion criteria: Blood sugar more than 400mg/dl,preganancy and lactating mothers,complications like hyperglycemic coma,ketoacidosis ,DM Neuropathy,retinopathy ,neuropathy ,Malignancy ,CVS disorders

Design outcomes

Primary

Measure	Time frame
glycaemic control (measured by glycosylated haemoglobin A1c (HbA1c) and fasting blood glucose levels) Timepoint: 2months	—

Secondary

Measure	Time frame
Assessment of adverse event by clinical evaluation, AE/SAE recording, Vitals and Lab Parameters ,Assessment of clinical global evaluation for overall efficacy by physician and by the patient , Assessment of overall acceptability/tolerability by Subject and physician Timepoint: 2months	—

Countries

India

Contacts

Public ContactDr Archana Kashid

D.Y.PATIL DEEMED TO BE UNIVERSITY SCHOOL OF AYURVEDA NERUL NAVIMUMBAI

ashishmhatre2010@gmail.com9819639895

Outcome results